News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Please Login or Become

Read More »

House GOP Effort to Amend 340B Falls Short in Key Committee

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to crucial budget legislation.

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to budget legislation integral to enacting congressional Democrats and the Biden administration’s Build Back Better plan.

Please Login or

Read More »

News Alert: Key House Committee Excludes “Spread Pricing” Language that 340B Entities Feared from Drug Pricing Legislation

The House Energy & Commerce Committee excluded spread-pricing language that 340B entities feared from forthcoming drug pricing legislation.

340B covered entities are breathing easier today upon learning that U.S. House Democrats excluded much-feared Medicaid managed care “spread pricing” language from forthcoming drug pricing legislation.

Please Login or Become a Paid Subscriber to View this

Read More »

N.C. Lawmakers Leave 340B DSH, Children’s, and Cancer Hospitals and HTCs Unprotected from PBM Pickpocketing

Hospital sign
North Carolina lawmakers excluded 340B disproportionate share hospitals, children’s hospitals, free-standing cancer hospitals, and hemophilia treatment centers from protection against discriminatory PBM treatment under a bill passed and sent to the governor this week.

North Carolina lawmakers approved a final deal Wednesday to protect some, but not all, of the state’s 340B covered entities against discrimination by pharmacy benefit managers (PBMs).

Please Login or Become a Paid Subscriber to View

Read More »

340B Report Publisher and CEO: Congress Needs to Intervene to Resolve Contract Pharmacy Impasse

The only expeditious path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky says.

The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

Read More »

Providers Concerned About Drug Pricing Reform’s Potential to Undermine 340B

340B covered entities are telling Congress that while they support federal action to lower drug prices, they worry that changes could weaken the 340B program and the wider health care safety net.

340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline

Passing a federal law to stem rising drug prices would have a modest effect on the U.S. prescription drug pipeline, a new CBO analysis finds.

Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in

Read More »

House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings

HHS Secretary Xavier Becerra's plan to fight excessive drug prices will be published publicly in the coming weeks, a White House official said yesterday.

As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue. While the proposals are going to be

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×